RT Journal Article
SR Electronic
T1 Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.22.22278669
DO 10.1101/2022.08.22.22278669
A1 Christinat, Yann
A1 Ho, Liza
A1 Clément, Sophie
A1 Genestie, Catherine
A1 Sehouli, Jalid
A1 Martin, Antonio Gonzalez
A1 Denison, Ursula
A1 Fujiwara, Keiichi
A1 Vergote, Ignace
A1 Tognon, Germana
A1 Hietanen, Sakari
A1 Ray-Coquard, Isabelle
A1 Pujade-Lauraine, Eric
A1 McKee, Thomas A.
YR 2022
UL http://medrxiv.org/content/early/2022/08/23/2022.08.22.22278669.abstract
AB BACKGROUND The efficiency of the Myriad Homologous Recombination Deficiency (HRD) test to guide use of PARP inhibitors has been demonstrated in several phase III trials. However its high failure rate and limited accessibility establish a need for a clinically validated laboratory developed test.PATIENTS AND METHODS A novel biomarker to identify HRD was developed using TCGA data and, as part of the ENGOT HRD European Initiative, applied to 469 samples from the PAOLA-1/ENGOT-ov25 phase 3 trial using the OncoScan™ CNV Assay. Results were compared to the Myriad myChoice Genomic Instability Score (GIS) with respect to the progression-free survival in the Olaparib+Bevacizumab and placebo+Bevacizumab arms.RESULTS Analysis of the TCGA cohort revealed that a normalization of the number of large-scale state transitions (nLST) by the number of whole genome doubling events allows a better separation and classification of HRD samples than the GIS. The Oncoscan+nLST test yielded a lower failure rate on the 469 PAOLA-1 samples (10/469 vs 59/469 inconclusive results) and positive and negative agreement values of 96% (204/213) and, 81% (159/197) respectively. In nLST-positive samples, the hazard ratio (HR) was 0.40 (95% CI: 0.28-0.57) compared with 0.35 for Myriad GIS. In tumors that were BRCA wild-type and nLST-positive, the HR was 0.53 (Myriad: 0.41). In this subpopulation the nLST test and the Myriad myChoice test yielded a similar 1-year PFS (87% and 88%) but a different 2-year PFS (52% vs 60%) upon Olaparib+ Bevacizumab treatment.CONCLUSION The proposed test is a viable alternative to the Myriad myChoice HRD test and can be easily deployed in a clinical laboratory for routine practice. The performance is similar to the commercial test but its lower failure rate allows a 10% increase in the number of patients who will receive a conclusive laboratory result.Highlights- A novel laboratory-developed test that increased HRD scoring accessibility for ovarian cancer patients- Clinically validated on 469 samples from the PAOLA-1 trial within the ENGOT HRD European Initiative- A similar performance as the Myriad myChoice Dx HRD test but at a lower failure rateCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by AstraZeneca, Cambridge, UK and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethic Committee "Comite de Protection des Personnes SUD-EST IV" of Centre Leon Berard, 28 rue Laennec, 69373 Lyon gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the present study produced from the TCGA cohort are available upon reasonable request to the authors. All data in the present study produced from the PAOLA-1 trial data are unavailable.All data in the present study produced from the TCGA cohort are available upon reasonable request to the authors. All data in the present study produced from the PAOLA-1 trial data are unavailable.